Intravenous Atropine in Reducing Reperfusion Arrhythmias, Conduction Abnormalities and Hypotension in Inferior ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

NCT07268586 | Completed Phase 4 FDA Drug

• 1 other identifier: FMASU R49/2025
• Study Type: interventional
• Target: 158
• Locations: 1 country
• Sites: 1

Brief Summary

People with acute inferior wall myocardial infarction will be given an intravenous drug called atropine that increases the heart rate to check if it prevents heart rhythm disturbances during performing coronary intervention

Conditions

Myocardial Infarction

Keywords

Atropine; Inferior ST elevation myocardial infarction

Outcome Measures

Primary Outcomes (2)

• Conduction abnormalities

  Occurrence of conduction abnormalities

  Periprocedurally

• Reperfusion arrhythmias

  Occurrence of reperfusion arrhythmias

  Periprocedurally

Secondary Outcomes (1)

• Major adverse cardiac events

  Periprocedurally

Study Arms (2)

Atropine arm

ACTIVE COMPARATOR

This group will receive intravenous atropine 1 mg immediately before wire crossing

Drug: Intravenous atropine immediately before wire crossing during primary percutaneous coronary intervention

Placebo arm

PLACEBO COMPARATOR

This group will receive intravenous normal saline immediately before wire crossing

Drug: Intravenous normal saline as placebo immediately before wire crossing during primary percutaneous coronary intervention

Interventions

Intravenous atropine immediately before wire crossing during primary percutaneous coronary intervention DRUG

Intravenous atropine 1 mg immediately before wire crossing during primary percutaneous coronary intervention

Atropine arm

Intravenous normal saline as placebo immediately before wire crossing during primary percutaneous coronary intervention DRUG

Intravenous normal saline as placebo immediately before wire crossing during primary percutaneous coronary intervention

Placebo arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Acute inferior ST elevation myocardial infarction

You may not qualify if:

• Execution of rescur percutaneous coronary intervention after thrombolysis
• Mechanical complications or no reflow or spontaneous reperfusion.
• Prior implantation of permanent or temporary pacemakers
• History of bradycardia, hypotension or ventricular tachycardia with a definitive cause (unrelated to the disease under study)
• Prior coronary artery bypass graft surgery
• Atropine contraindications Unwillingness to participate in the

Sponsors & Collaborators

• Ain Shams University: lead

Study Sites (1)

Ain Shams University

Cairo, Abbasia, Egypt

Location

MeSH Terms

Conditions

Myocardial Infarction

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 1, 2025
• First Posted: December 8, 2025
• Study Start: August 1, 2025
• Primary Completion: February 28, 2026
• Study Completion: February 28, 2026
• Last Updated: March 10, 2026

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)